Stocks › BBIO

BridgeBio Pharma, Inc.

BBIO·Nasdaq·United States United States·USD
$76.03
-2.15 (-2.75%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
BBIO
BridgeBio Pharma, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
BBIOS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of BBIO by members of U.S. Congress · 10 on record · 8 in the last 12 months
All congressional trades →

Whale Activity

Position changes in BBIO reported for 2026-09-30 by 531 institutional filers
Increased: 187New: 60Held: 60Decreased: 144Closed: 60No prior filing: 20
  • Increased187
  • New60
  • Held60
  • Decreased144
  • Closed60
  • No prior filing20
FilerSharesValueChange
Janus Henderson Group Ltd.14.6M$957.7M—
FARALLON CAPITAL MANAGEMENT, L.L.C.14.2M$937.5Mincreased
BlackRock, Inc.10.4M$683.6Mincreased
VIKING GLOBAL INVESTORS LP9.8M$644.3Mdecreased
WELLINGTON MANAGEMENT GROUP LLP9.5M$622.4Mincreased
Kohlberg Kravis Roberts & Co. L.P.8.3M$543.6Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC7.9M$520.7Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC7.5M$492.5Mdecreased
STATE STREET CORP5.0M$327.5Mincreased
Invesco Ltd.4.3M$284.1Mincreased
JPMORGAN CHASE & CO4.0M$264.5Mincreased
FRANKLIN TEMPLETON INC3.3M$255.4Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by BBIO insiders, by quarter · Form 4
-10.0M-5.0M05.0M10.0M2025 Q1: -9.9M2025 Q12025 Q2: -9.9M2025 Q22025 Q3: -717.9K2025 Q32025 Q4: -707.2K2025 Q42026 Q1: -393.2K2026 Q12026 Q2: -426.4K2026 Q22026 Q3: -222.7K2026 Q32026 Q4: -57.0K2026 Q4

Recent Insider Transactions

778 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Kumar NeilChief Executive Officer · Director Sale −8,500 $78.35 $666K Nov 19, 2026 Form 4 ↗
Kumar NeilChief Executive Officer · Director Sale −1,500 $79.29 $119K Nov 19, 2026 Form 4 ↗
Kumar NeilChief Executive Officer · Director Sale −8,723 $77.83 $679K Nov 18, 2026 Form 4 ↗
Kumar NeilChief Executive Officer · Director Sale −4,490 $76.99 $346K Nov 18, 2026 Form 4 ↗
Kumar NeilChief Executive Officer · Director Sale −30.5K $77.83 $2.4M Nov 18, 2026 Form 4 ↗
Kumar NeilChief Executive Officer · Director Sale −1,277 $76.99 $98K Nov 18, 2026 Form 4 ↗
Apuli MaricelChief Accounting Officer Sale −2,000 $72.85 $146K Oct 30, 2026 Form 4 ↗
Kumar NeilChief Executive Officer · Director Sale −1,279 $69.57 $89K Sep 17, 2026 Form 4 ↗
Kumar NeilChief Executive Officer · Director Sale −8,721 $69.01 $602K Sep 17, 2026 Form 4 ↗
Kumar NeilChief Executive Officer · Director Sale −100 $85.65 $9K Aug 19, 2026 Form 4 ↗
Kumar NeilChief Executive Officer · Director Sale −1,800 $84.69 $152K Aug 19, 2026 Form 4 ↗
Kumar NeilChief Executive Officer · Director Sale −8,100 $83.86 $679K Aug 19, 2026 Form 4 ↗
Kumar NeilChief Executive Officer · Director Sale −1,199 $83.77 $100K Aug 18, 2026 Form 4 ↗
Kumar NeilChief Executive Officer · Director Sale −14.6K $82.99 $1.2M Aug 18, 2026 Form 4 ↗
Kumar NeilChief Executive Officer · Director Sale −17.3K $82.21 $1.4M Aug 18, 2026 Form 4 ↗
Kumar NeilChief Executive Officer · Director Sale −1,900 $81.15 $154K Aug 18, 2026 Form 4 ↗
Trimarchi ThomasPresident and CFO Tax withholding −22.8K $79.86 $1.8M Aug 16, 2026 Form 4 ↗
Kumar NeilChief Executive Officer · Director Tax withholding −36.2K $79.86 $2.9M Aug 16, 2026 Form 4 ↗
Kumar NeilChief Executive Officer · Director Option exercise +6,520 — — Aug 16, 2026 Form 4 ↗
Kumar NeilChief Executive Officer · Director Option exercise +11.6K — — Aug 16, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding BBIO · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
5.6M$417.1M0.02%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
4.0M$300.9M0.16%Jun 30, 2026
VANGUARD HEALTH CARE FUND
VANGUARD SPECIALIZED FUNDS
3.2M$253.3M0.66%Jul 31, 2026
VANGUARD SMALL-CAP GROWTH INDEX FUND
VANGUARD INDEX FUNDS
2.3M$173.6M0.37%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
2.0M$147.1M0.15%Jun 30, 2026
Janus Henderson Enterprise Fund
Janus Investment Fund
1.9M$142.2M0.64%Jun 30, 2026
VANGUARD EXPLORER FUND1.7M$138.2M0.62%Jul 31, 2026
Janus Henderson Global Life Sciences Fund
Janus Investment Fund
1.6M$118.5M2.04%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
1.6M$111.5M0.34%Apr 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
1.5M$110.0M1.02%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list BBIO's shares (CUSIP 10806X102), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Linn, Michael G.SCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
    Nov 12, 2026 · ↗
  • Kim, David T.SCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
    Nov 12, 2026 · ↗
  • Husen, Avner A.SCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
    Nov 12, 2026 · ↗
  • Giauque, NicolasSCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
    Nov 12, 2026 · ↗
  • Gehani, Varun N.SCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
    Nov 12, 2026 · ↗
  • Dunn Hannah E.SCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
    Nov 12, 2026 · ↗
  • Dreyfuss, Philip D.SCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
    Nov 12, 2026 · ↗
  • Dapice Joshua J.SCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
    Nov 12, 2026 · ↗
  • Wehrly, Mark C.SCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
    Nov 12, 2026 · ↗
  • Warren, John R.SCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
    Nov 12, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming BridgeBio Pharma, Inc. as client

No lobbying filings found naming BridgeBio Pharma, Inc. as the client.

Government Contracts

Federal awards to BridgeBio Pharma, Inc. · USAspending

No federal contract awards found for BridgeBio Pharma, Inc..

U.S. Patents

Recent USPTO applications naming BridgeBio Pharma, Inc.

No USPTO patent applications found for BridgeBio Pharma, Inc..

Annual Financials

From BBIO's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$502.1M$221.9M$9.3M$77.6M$69.7M
Operating income-$523.4M-$593.0M-$607.4M-$512.2M-$576.6M
Diluted EPS-$3.78-$2.88-$3.95-$3.26-$3.90
Operating cash flow-$445.9M-$520.7M-$527.7M-$419.5M-$497.9M
Cash and equivalents$570.1M$681.1M$375.9M$376.7M$393.8M
Total assets$936.0M$919.3M$546.4M$623.0M$1.01B
Total liabilities$3.01B$2.38B$1.89B$1.87B$1.88B
Shareholders' equity-$2.09B-$1.47B-$1.35B-$1.25B-$870.4M

As BridgeBio Pharma, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 24, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in BBIO's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsOct 29, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsOct 13, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsAug 31, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 8.01, 9.01Material agreement · Other eventsAug 17, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 10, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsJul 22, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 3.02, 3.03, 5.03, 7.01, 9.01Material agreement · Unregistered sale of equity · Modification of rightsJul 2, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 26, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsMay 27, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsMay 13, 2026
    EDGAR ↗

About BridgeBio Pharma, Inc.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersPALO ALTO, CA
IncorporatedDE
Former namesBridgeBio Pharma LLC